Brainstorm Cell Therapeutics Inc  

(Public, NASDAQ:BCLI)   Watch this stock  
Find more results for OTC:BCLI
2.24
-0.16 (-6.67%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.20 - 2.36
52 week 1.90 - 4.02
Open 2.36
Vol / Avg. 71,960.00/59,297.00
Mkt cap 39.16M
P/E     -
Div/yield     -
EPS -0.46
Shares 18.65M
Beta 0.57
Inst. own 12%
May 12, 2016
Q1 2016 Brainstorm Cell Therapuetics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 22, 2016
ARM's (Alliance for Regenerative Medicine) Cell & Gene Investor Day - Webcast
Mar 15, 2016
Brainstorm Cell Therapuetics Inc at Biotechnology Innovation Organization (BIO) Asia International Conference
Mar 10, 2016
Q4 2015 Brainstorm Cell Therapuetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -31.33% -62.90%
Return on average equity -37.45% -81.60%
Employees 17 -
CDP Score - -

Address

3 University Plaza Drive, Suite 320
HACKENSACK, NJ 07601
United States - Map
+1-201-4880460 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Officers and directors

Irit Arbel Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Chaim Lebovits Chief Executive Officer
Age: 44
Bio & Compensation  - Reuters
Yoram Bibring Chief Financial Officer, Treasurer
Age: 57
Bio & Compensation  - Reuters
Uri Yablonka Chief Operating Officer, Director
Age: 38
Bio & Compensation  - Reuters
Alla Patlis Controller
Age: 28
Bio & Compensation  - Reuters
Mordechai Friedman Independent Director
Age: 62
Bio & Compensation  - Reuters
Alon Pinkas Independent Director
Age: 54
Bio & Compensation  - Reuters
Chen Schor CPA Independent Director
Age: 42
Bio & Compensation  - Reuters
Robert G L Shorr Independent Director
Age: 57
Bio & Compensation  - Reuters
Malcolm Taub Independent Director
Age: 69
Bio & Compensation  - Reuters